Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 2/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL7315527 | 0.89 | SLC6A9 (0.64) | SLC6A9SLC6A2SLC6A4CYP1A2CYP3A4 | |
| Fumaric Acid SCHEMBL7315531 | 0.89 | SLC6A9 (0.64) | SLC6A9SLC6A2SLC6A4CYP1A2CYP3A4 | |
| SCHEMBL8197707 | 0.84 | CYP2D6 (0.64) | SLC6A9SLC6A2SLC6A4CYP1A2CYP3A4 | |
| SCHEMBL3894545 | 0.84 | CYP2D6 (0.64) | SLC6A9SLC6A2SLC6A4CYP1A2CYP3A4 | |
| SCHEMBL5078074 | 0.84 | SLC6A4 (0.59) | SLC6A9SLC6A4HRH3 | |
| SCHEMBL9398414 | 0.83 | SLC6A9 (0.63) | SLC6A9SLC6A2SLC6A4CYP1A2CYP3A4 | |
| SCHEMBL8024681 | 0.83 | SLC6A4 (0.53) | SLC6A9SLC6A2SLC6A4CYP1A2CYP3A4 | |
| SCHEMBL7169436 | 0.82 | SLC6A4 (0.52) | SLC6A9SLC6A2SLC6A4CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL7320057 | 0.82 | SLC6A4 (0.56) | SLC6A9SLC6A2SLC6A4CYP1A2CYP3A4 | |
| SCHEMBL17835592 | 0.82 | SLC6A9 (0.56) | SLC6A9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266882-A1 | Aryloxypropylamines as chemosensitizing agents in the treatment of cancer | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2004-12-30 | — | — | US | disclosed |
| EP-1425002-A1 | ARYLOXYPROPYLAMINES AS CHEMOSENSITIZING AGENTS IN THE TREATMENT OF CANCER | Ramot at Tel Aviv University Ltd. (IL) | 2004-06-09 | — | — | EP | disclosed |
| US-20040054014-A1 | Method and pharmaceutical compositions forthe treatment of cancer | RAMOT AT TEL AVIV UNIVERSITY LTD. | 2004-03-18 | — | — | US | disclosed |
| US-6630454-B2 | Method and pharmaceutical composition for the treatment of cancer | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2003-10-07 | — | — | US | disclosed |
| US-20030087964-A1 | Method and pharmaceutical composition for the treatment of cancer | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. | 2003-05-08 | — | — | US | disclosed |
| WO-2003022258-A1 | ARYLOXYPROPYLAMINES AS CHEMOSENSITIZING AGENT IN THE TREATMENT OF CANCER | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2003-03-20 | — | — | WO | disclosed |
| EP-0318727-B1 | Aryloxphenylpropylamines and their preparation and use | NOVO NORDISK AS (DK) | 1994-03-09 | — | — | EP | disclosed |
| US-4970232-A | CALCIUM CHANNEL BLOCKERS; ANOXIA, ANTIEPILEPTIC AND ANTIISCHEMIC AGENTS; HEADACHES | A/S FERROSAN (DK) | 1990-11-13 | — | — | US | disclosed |
| US-4962122-A | TREATMENT OF ANOXIA, MIGRAINE, ISCHEMIA AND EPILIEPSY | A/S FERROSAN (DK) | 1990-10-09 | — | — | US | disclosed |
| EP-0318727-A2 | Aryloxphenylpropylamines and their preparation and use | NOVO NORDISK A/S (DK) | 1989-06-07 | — | — | EP | disclosed |
| US-4626549-A | Treatment of obesity with aryloxyphenylpropylamines | ELI LILLY AND COMPANY (US) | 1986-12-02 | — | — | US | disclosed |
| US-4314081-A | ANTIDEPRESSANTS | ELI LILLY AND COMPANY (US) | 1982-02-02 | — | — | US | disclosed |
| US-4194009-A | ANTIDEPRESSANT | ELI LILLY AND COMPANY (US) | 1980-03-18 | — | — | US | disclosed |
| US-4018895-A | Aryloxyphenylpropylamines in treating depression | ELI LILLY AND COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054014-A1 | Method and pharmaceutical compositions forthe treatment of cancer | ABCC1, ABCB1, SLC11A2 | SLC6A9 1153/4885SLC6A2 374/4885SLC6A4 340/4885 |
| US-20030087964-A1 | Method and pharmaceutical composition for the treatment of cancer | PNMT, ABCC1, HNMT | SLC6A9 2429/4885SLC6A2 550/4885SLC6A4 596/4885 |
| US-20040266882-A1 | Aryloxypropylamines as chemosensitizing agents in the treatment of cancer | ABCC1, PNMT, ABCB1 | SLC6A9 2252/4885SLC6A2 290/4885SLC6A4 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.